Santarus Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 290

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.6B

Santarus General Information

Description

Provider of pharmaceutical products for the treatment of upper and lower gastrointestinal diseases and disorders. The company focus on the development and commercialization of next generation proton pump inhibitor, or PPI, products the most frequently prescribed drugs for the treatment of many upper gastrointestinal, or GI, diseases and disorders.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Corporate Office
  • 3611 Valley Centre Drive
  • Suite 400
  • San Diego, CA 92130
  • United States
+1 (858) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Santarus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 03-Jan-2014 $2.6B 00000 00.00 Completed Generating Revenue
7. Debt - General 01-Aug-2006 00000 Completed Generating Revenue
6. PIPE 00000 Completed Generating Revenue
5. IPO 01-Apr-2004 0000 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series D) 19-May-2003 000.00 000.00 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 07-Mar-2001 000.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Jan-1999 $5.28M $5.34M 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Dec-1996 $62K $62K 00000 Completed Product Development
To view Santarus’s complete valuation and funding history, request access »

Santarus Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 5,276,000 $0.000100 8% $1 $1 1x $1 5.08%
Series A 620,000 $0.000100 5% $0.1 $0.1 1x $0.1 0.6%
To view Santarus’s complete cap table history, request access »

Santarus Patents

Santarus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240131026-A1 Bromocriptine formulations Pending 26-Apr-2023 00000000000
AU-2015222756-A1 Treatment of hereditary angioedema with c1 inhibitor Inactive 28-Feb-2014 000000000
EP-3110508-A1 Treatment of hereditary angioedema with c1 inhibitor Inactive 28-Feb-2014 000000000
CA-2940670-A1 Treatment of hereditary angioedema with c1 inhibitor Inactive 28-Feb-2014 000000000
EP-3110508-A4 Treatment of hereditary angioedema with c1 inhibitor Inactive 28-Feb-2014 A61K38/55
To view Santarus’s complete patent history, request access »

Santarus Executive Team (16)

Name Title Board Seat Contact Info
Jonathan Hee Vice President, Commercial Affairs
Gerald Proehl President & Chief Executive Officer
Warren Hall Senior Vice President, Manufacturing and Product Development
You’re viewing 3 of 16 executive team members. Get the full list »

Santarus Board Members (8)

Name Representing Role Since
Alessandro Della Chà Self Board Member 000 0000
Kent Snyder Self Board Member 000 0000
Ted Love MD Self Board Member 000 0000
You’re viewing 3 of 8 board members. Get the full list »

Santarus Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Santarus Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Advent Life Sciences Venture Capital Minority 000 0000 000000 0
Advent Venture Partners Venture Capital Minority 000 0000 000000 0
CDIB BioScience Venture Management Venture Capital Minority 000 0000 000000 0
Domain Associates Venture Capital Minority 000 0000 000000 0
EQT Life Sciences Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

Santarus Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Lifecycle Pharma (Fenoglide) 21-Dec-2011 000000000 Buildings and Property
Covella Pharmaceuticals 10-Sep-2010 Merger/Acquisition 00000 Biotechnology 000000 00
To view Santarus’s complete investments and acquisitions history, request access »

Santarus FAQs

  • When was Santarus founded?

    Santarus was founded in 1996.

  • Who is the CEO of Santarus?

    Gerald Proehl is the CEO of Santarus.

  • Where is Santarus headquartered?

    Santarus is headquartered in San Diego, CA.

  • What is the size of Santarus?

    Santarus has 290 total employees.

  • What industry is Santarus in?

    Santarus’s primary industry is Pharmaceuticals.

  • Is Santarus a private or public company?

    Santarus is a Private company.

  • What is the current valuation of Santarus?

    The current valuation of Santarus is 00.00.

  • What is Santarus’s current revenue?

    The current revenue for Santarus is 00000.

  • How much funding has Santarus raised over time?

    Santarus has raised $144M.

  • Who are Santarus’s investors?

    Advent Life Sciences, Advent Venture Partners, CDIB BioScience Venture Management, Domain Associates, and EQT Life Sciences are 5 of 17 investors who have invested in Santarus.

  • When was Santarus acquired?

    Santarus was acquired on 03-Jan-2014.

  • Who acquired Santarus?

    Santarus was acquired by Salix Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »